Try
Ionis Pharmaceuticals Inc.
IONSUnited States
52 filed reports · 504 financial concepts · 2 earnings calls · 1 media appearances
Filed reports
52 reports · Jun 2016 to Jun 2026Each report counts once it has at least one extracted financial fact. Also extracted from these reports: 26 guidance figures.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 31 | 4,997 | Jun 2016 to Jun 2026 |
| Current · 8-KSEC EDGAR | 11 | 26 | Dec 2020 to Mar 2026 |
| Annual · 10-KSEC EDGAR | 10 | 5,223 | Dec 2016 to Dec 2025 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2026 Q2 | 10-Q | Jun 30, 2026 | Jul 29, 2026 | 369 | Open |
| FY2026 Q1 | 8-K | Mar 31, 2026 | Apr 29, 2026 | 4 | Open |
| FY2026 Q1 | 10-Q | Mar 31, 2026 | Apr 29, 2026 | 236 | Open |
| FY2025 | 10-K | Dec 31, 2025 | Feb 26, 2026 | 919 | Open |
| FY2025 Q4 | 8-K | Dec 31, 2025 | Feb 25, 2026 | 4 | Open |
| FY2025 Q3 | 10-Q | Sep 30, 2025 | Oct 29, 2025 | 238 | Open |
| FY2025 Q3 | 8-K | Sep 30, 2025 | Oct 29, 2025 | 4 | Open |
| FY2025 Q2 | 10-Q | Jun 30, 2025 | Jul 30, 2025 | 157 | Open |
| FY2025 Q2 | 8-K | Jun 30, 2025 | Jul 30, 2025 | 2 | Open |
| FY2025 Q1 | 8-K | Mar 31, 2025 | Apr 30, 2025 | 2 | Open |
| FY2025 Q1 | 10-Q | Mar 31, 2025 | Apr 30, 2025 | 161 | Open |
| FY2024 | 10-K | Dec 31, 2024 | Feb 19, 2025 | 487 | Open |
Financial data
504 concepts · 10,246 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial481 concepts · 9,156 facts · Dec 2014 to Jul 2026
- Corporate Debt Securities92 · Dec 2021 to Jun 2026
- Total75 · Jun 2016 to Jun 2026
- Cash and cash equivalents at carrying value58 · Dec 2014 to Jun 2026
- Net income loss58 · Dec 2014 to Jun 2026
- Operating income loss58 · Dec 2014 to Jun 2026
- Revenue58 · Dec 2014 to Jun 2026
- Allocated share based compensation expense57 · Dec 2014 to Jun 2026
- Comprehensive income net of tax57 · Dec 2014 to Jun 2026
- Earnings per share basic57 · Mar 2015 to Jun 2026
- Earnings per share diluted57 · Mar 2015 to Jun 2026
- Income tax expense benefit57 · Dec 2014 to Jun 2026
- Interest expense (US GAAP)57 · Dec 2014 to Jun 2026
- Investment income net57 · Dec 2014 to Jun 2026
- Accretion amortization of discounts and premiums investments56 · Dec 2014 to Jun 2026
- Amortization of financing costs56 · Dec 2014 to Jun 2026
- Depreciation56 · Dec 2014 to Jun 2026
- Increase decrease in accounts payable56 · Dec 2014 to Jun 2026
- Increase decrease in inventories56 · Dec 2014 to Jun 2026
- Increase decrease in other employee related liabilities56 · Dec 2014 to Jun 2026
- Increase decrease in other operating assets56 · Dec 2014 to Jun 2026
- Payments to acquire available for sale securities debt56 · Dec 2014 to Jun 2026
- Payments to acquire property plant and equipment56 · Dec 2014 to Jun 2026
- Proceeds from sale and maturity of available for sale securities56 · Dec 2014 to Jun 2026
- Share based compensation56 · Dec 2014 to Jun 2026
Segment16 concepts · 661 facts · Dec 2014 to Jun 2026
- Revenue283 · Dec 2014 to Jun 2026
- Operating income loss60 · Dec 2014 to Dec 2020
- Total Assets50 · Dec 2015 to Dec 2020
- Costs and expenses32 · Dec 2017 to Dec 2020
- Net income loss32 · Sep 2017 to Jun 2026
- Operating expenses (US GAAP)30 · Dec 2015 to Dec 2018
- Research and development revenue under collaborative agreements30 · Dec 2014 to Dec 2017
- Total commercial revenue28 · Dec 2014 to Dec 2017
- Licensing and other royalty revenue22 · Dec 2015 to Dec 2017
- Allocated share based compensation expense15 · Jun 2015 to Mar 2018
- Cost of goods and services sold (US GAAP)14 · Dec 2022 to Jun 2026
- Ionis Operations14 · Dec 2022 to Jun 2026
- Segment reporting other item amount14 · Dec 2022 to Jun 2026
- Selling general and administrative expense14 · Dec 2022 to Jun 2026
- Royalty revenue12 · Dec 2016 to Dec 2017
- Revenue from contracts with customers (excluding tax)11 · Dec 2016 to Dec 2017
Product4 concepts · 403 facts · Dec 2016 to Jun 2026
- Revenue395 · Dec 2016 to Jun 2026
- Revenue (excluding assessed tax)4 · Mar 2017 to Jun 2025
- Decrease in revenue from amortization of payments using input method under new revenue guidance2 · Dec 2016 to Dec 2017
- Increase in revenue from amortization of milestone payments achieved under new revenue guidance2 · Dec 2016 to Dec 2017
Guidance3 concepts · 26 facts · Feb 2021 to Apr 2026
- Revenue Guidance16 · Feb 2021 to Apr 2026
- Operating Income Guidance8 · Feb 2024 to Apr 2026
- Net Income Guidance2 · Aug 2021 to Feb 2022
Segments
1,064 factsFigures broken down by business line, region, product or another axis the company reports on.
Statement business segments5 members · 661 facts
- Ionis Core265 · Dec 2014 to Dec 2020
- Akcea Therapeutics262 · Dec 2014 to Dec 2020
- Ionis Operations84 · Dec 2022 to Jun 2026
- Akcea therapeutics25 · Dec 2015 to Dec 2020
- Ionis core25 · Dec 2015 to Dec 2020
Product or servicesrt:ProductOrServiceAxis25 members · 395 facts
- Commercial47 · Dec 2016 to Jun 2026
- Product43 · Dec 2016 to Jun 2026
- Licensing And Other Royalties38 · Dec 2016 to Sep 2024
- Spinraza Royalties37 · Dec 2018 to Jun 2026
- Research And Development Revenue Under Collaborative Agreements29 · Dec 2016 to Dec 2021
- Collaborative Agreement Revenue28 · Dec 2020 to Jun 2026
- Research And Development Revenue28 · Dec 2020 to Jun 2026
- Wainua Joint Development Revenue28 · Dec 2020 to Jun 2026
- Other Commercial21 · Dec 2021 to Jun 2026
- Wainus Royalties18 · Dec 2022 to Jun 2026
- SPINRAZA Royalties16 · Dec 2016 to Mar 2020
- Other Royalties13 · Dec 2023 to Jun 2026
- Royalty13 · Dec 2023 to Jun 2026
- Tryngolza8 · Mar 2024 to Jun 2026
- Other7 · Dec 2022 to Jun 2025
- DAWNZERA Sales4 · Mar 2025 to Jun 2026
- Tegsedi And Waylivra4 · Mar 2024 to Jun 2025
- Dawnzera Sales3 · Dec 2023 to Dec 2025
- Tryngolza Sales3 · Dec 2023 to Dec 2025
- TEGSEDI Product Sales2 · Jun 2018 to Jun 2019
- Ion8591 · Mar 2022
- Ion8591 · Mar 2022
- Licensing and other royalties1 · Nov 2017
- Other1 · Jun 2025
- Research and development revenue under collaborative agreements1 · Mar 2017
Product or serviceus-gaap:ProductOrServiceAxis4 members · 8 facts
- Commercial2 · Mar 2017 to Mar 2018
- Licensing And Other Royalties2 · Mar 2017 to Mar 2018
- Research And Development Under Collaborative Agreements2 · Mar 2017 to Mar 2018
- SPINRAZA Royalties2 · Mar 2017 to Mar 2018
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
- Earnings-release commentary130 claims from 9 reports · Sep 2024 to Jun 2026
- Management discussion (MD&A) commentary38 claims from 2 reports · Dec 2024 to Dec 2025
- Risk-factor changes9 claims from 1 reports · Dec 2025
- Risk factors80 risks from 2 annual reports · 2024 to 2025
Earnings calls
2 calls · Apr 2026 to Jul 2026Transcripts with management claims and analyst questions, one per fiscal period.
- FY2026 Q2Jul 29, 2026
- FY2026 Q1Apr 29, 2026
Executive media
1 appearancesPodcasts, interviews and conference appearances by the company's executives, with their claims.
- TV interviews1 · Oct 2025
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.